The main advantage of this study is proving that there were differences in GFAP and UCH-L1 serum levels between SVO and LVO patients and, also, furthering knowledge of less-researched UCH-L1 in the setting of AIS. This evidence concerns the gene GFAP and androgen insensitivity syndrome.